Akari Therapeutics, Plc

Akari Therapeutics, Plc is a biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity.

The company's pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric HSCT-TMA. It has also obtained an orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation.

Akari's ongoing clinical program is focused on developing nomacopan for adult HSCT-TMA and conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA).

Founded in 2004 and headquartered in the United Kingdom, with its most recent $2.00M Post-IPO Equity investment raised at 21 September 2023, with Samir R Patel and Ray Prudo as the investors, Akari Therapeutics is well-positioned to make significant strides in addressing unmet medical needs in the realm of autoimmune and inflammatory diseases.